Study Evaluating Effexor XR for Major Depression.

Phase 3

Completed

• Conditions: Depression

• Registration Number: NCT00225511
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

Study Evaluating Effexor XR for Major Depression.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-06
• Study First Submitted: 2005-09-12
• Study First Submitted QC: 2005-09-20
• Study First Posted: 2005-09-23
• Status Verified: 2007-05
• Last Update Submitted: 2007-05-22
• Last Update Posted: 2007-05-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 590

Inclusion Criteria

• Patients diagnosed with major depression based on DSM-IV-TR
• Patients having minimal total score of 18 on the HAM-D17 and minimal score of 2 on the item of "depressed mood" at the baseline.

Exclusion Criteria

• Patients with schizophrenia or any other psychotic disorder
• Patients with history or presence of bipolar disorder

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Response rate of HAM-D17 (Hamilton Rating Scale for Depression) at the final-on-therapy.

Secondary Outcome Measures

Name	Time	Method
Difference of total score of HAM-D17 between baseline and final-on-therapy.
Remission rate of HAM-D17 at the final-on-therapy.